Botulinum toxin type B: an open-label, dose-escalation, safety and preliminary efficacy study in cervical dystonia patients
Cullis, P.A.; O'Brien, C.F.; Truong, D.D.; Koller, M.; Villegas, T.P.; Wallace, J.D.
Advances in Neurology 78: 227-230
1998
ISSN/ISBN: 0091-3952 PMID: 9750919 Document Number: 489896
Document emailed within 1 workday
Related Documents
Rubin, M.G.; Dover, J.; Glogau, R.G.; Goldberg, D.J.; Goldman, M.P.; Schlessinger, J. 2009: The efficacy and safety of a new U.S. Botulinum toxin type a in the retreatment of glabellar lines following open-label treatment Journal of Drugs in Dermatology: Jdd 8(5): 439-444Cohen, J.L.; Dayan, S.H. 2006: Botulinum toxin type a in the treatment of dermatochalasis: an open-label, randomized, dose-comparison study Journal of Drugs in Dermatology: Jdd 5(7): 596-601
Dykstra, D.D.; Presthus, J. 2006: Botulinum toxin type A for the treatment of provoked vestibulodynia: an open-label, pilot study Journal of Reproductive Medicine 51(6): 467-470
Adachi, M.; Saura, R. 2006: Initial efficacy of intramuscular injection of botulinum toxin type A against cervical dystonia and general muscular hypertonia in persons with severe motor and intellectual disabilities No to Hattatsu 38(6): 425-430
Comella, C.L.; Jankovic, J.; Brin, M.F. 2000: Use of botulinum toxin type a in the treatment of cervical dystonia Neurology 55(12 Suppl 5: S15-S21
Fearon, K.C.; Falconer, J.S.; Ross, J.A.; Carter, D.C.; Hunter, J.O.; Reynolds, P.D.; Tuffnell, Q. 1996: An open-label phase I/Ii dose escalation study of the treatment of pancreatic cancer using lithium gammalinolenate Anticancer Research 16(2): 867-874
Wiegratz, I.; Bassol, S.; Weisberg, E.; Mellinger, U.; Merz, M. 2014: Effect of a low-dose contraceptive patch on efficacy, bleeding pattern, and safety: a 1-year, multicenter, open-label, uncontrolled study Reproductive Sciences 21(12): 1518-1525
Semmanaselvan, K.; Mukaddam, Q.I.; Naik, M. 2015: An Open Label, Prospective, Single Centre Study to Evaluate the Efficacy and Safety of Fixed Dose Combination of Rabeprazole (Enteric-Coated, EC) 20 mg + Domperidone (Sustained Release, SR) 30 mg Capsule in Treatment of Patients with Laryngopharyngeal Reflux Disease Journal of the Association of Physicians of India 63(7): 27-32
Glogau, R.; Blitzer, A.; Brandt, F.; Kane, M.; Monheit, G.D.; Waugh, J.M. 2012: Results of a randomized, double-blind, placebo-controlled study to evaluate the efficacy and safety of a botulinum toxin type a topical gel for the treatment of moderate-to-severe lateral canthal lines Journal of Drugs in Dermatology: Jdd 11(1): 38-45
Kwanchuay, P.; Petchnumsin, T.; Yiemsiri, P.; Pasuk, N.; Srikanok, W.; Hathaiareerug, C. 2015: Efficacy and Safety of Single Botulinum Toxin Type A (Botox®) Injection for Relief of Upper Trapezius Myofascial Trigger Point: A Randomized, Double-Blind, Placebo-Controlled Study Journal of the Medical Association of Thailand 98(12): 1231-1236
Esteghamati, A.; Rajabian, R.; Amini, M.; Bahrami, A.; Khamseh, M.E.; Afkhami-Ardekani, M.; Rizi, E.P. 2010: The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study--the Iran subgroup of the IMPROVE™ study Endokrynologia Polska 61(4): 364-370
Bhaumik, S.; Behari, M. 1999: Botulinum toxin A--injection for cervical dystonia Journal of the Association of Physicians of India 47(3): 267-270
Sławek, J.ła.; Cielecka, A.; Duzyński, W. 2002: Prognostic factors of long-standing improvement in cervical dystonia, treated with botulinum a toxin Neurologia i Neurochirurgia Polska 36(1): 47-56
Wanichwecha-Rungruang, B.; Iemsomboon, W. 2005: Efficacy and safety of bimatoprost for the treatment of open-angle glaucoma and ocular hypertension: a three-month, open-label study in community-based practices in Thailand Journal of the Medical Association of Thailand 88(9): 1228-1235
Yokota, S.; Imagawa, T.; Nishikomori, R.; Takada, H.; Abrams, K.; Lheritier, K.; Heike, T.; Hara, T. 2017: Long-term safety and efficacy of canakinumab in cryopyrin-associated periodic syndrome: results from an open-label, phase IIi pivotal study in Japanese patients Clinical and Experimental Rheumatology 35 Suppl 108(6): 19-26
Saple, D.G.; Torsekar, R.G.; Pawanarkar, V.; Wali, V.; Ravichandran, G.; Dhanalakshmi, U.R.; Dongre, N.; Ballary, C.; Desai, A. 2003: Evaluation of the efficacy, safety and tolerability of Tacrolimus ointment in Indian patients of moderate to severe atopic dermatitis: a multicentric, open label, phase IIi study Indian Journal of Dermatology Venereology and Leprology 69(6): 396-400
Vender, R. 2011: An open-label, prospective cohort pilot study to evaluate the efficacy and safety of etanercept in the treatment of moderate to severe plaque psoriasis in patients who have not had an adequate response to adalimumab Journal of Drugs in Dermatology: Jdd 10(4): 396-402
Elewski, B.E.; Cantrell, W.C. 2011: An open-label study of the safety and efficacy of sertaconazole nitrate in the treatment of seborrheic dermatitis Journal of Drugs in Dermatology: Jdd 10(8): 895-899
Iwashige, H.; Nemeto, Y.; Takahashi, H.; Maruo, T. 1995: Botulinum toxin type a purified neurotoxin complex for the treatment of blepharospasm: a dose-response study measuring eyelid force Japanese Journal of Ophthalmology 39(4): 424-431
Adler, L.A.; Spencer, T.J.; Williams, D.W.; Moore, R.J.; Michelson, D. 2008: Long-term, open-label safety and efficacy of atomoxetine in adults with ADHD: final report of a 4-year study Journal of Attention Disorders 12(3): 248-253